<?xml version="1.0" encoding="utf-8" ?>
<feed xmlns="http://www.w3.org/2005/Atom">
<title>Raghuraj123 - Latest News</title>
<link href="https://news.arcnewswire.com/rss/raghuraj123/latest.xml"></link>
<updated>2026-09-20T08:04:37+00:00</updated>
<id>urn:uuid:c9f5ac39-4ccf-e75e-173f-eb996e71229e</id>
<entry>
<title>New study on Arterial Thrombosis Global Market Clinical Trials Review, H2, 2016</title>
<link href="https://news.arcnewswire.com/@raghuraj123/new-study-on-arterial-thrombosis-global-market-clinical-trials-review-h2-2016-6p3w6ykpp85y"></link>
<id>urn:uuid:06efc6c8-4bf7-52e0-9bdb-0196afbbf06e</id>
<summary type="html"><![CDATA[GlobalData's clinical trial report, Arterial Thrombosis Global Clinical Trials Review, H2, 2016" provides an overview of Arterial Thrombosis clinical trials scenario.]]></summary>
<updated>2016-09-13T05:41:42+00:00</updated>
</entry>
<entry>
<title>New study on Atrial Septal Defect Global Market Clinical Trials Review, H2, 2016</title>
<link href="https://news.arcnewswire.com/@raghuraj123/new-study-on-atrial-septal-defect-global-market-clinical-trials-review-h2-2016-b68qwb76w8dj"></link>
<id>urn:uuid:46e489f1-70f8-4533-7953-32f045fcd892</id>
<summary type="html"><![CDATA[GlobalData's clinical trial report, Atrial Septal Defect Global Clinical Trials Review, H2, 2016" provides an overview of Atrial Septal Defect clinical trials scenario.]]></summary>
<updated>2016-09-13T05:40:38+00:00</updated>
</entry>
<entry>
<title>New study on Critical Limb Ischemia Global Market Clinical Trials Review, H2, 2016</title>
<link href="https://news.arcnewswire.com/@raghuraj123/new-study-on-critical-limb-ischemia-global-market-clinical-trials-review-h2-2016-6a356r7a48xd"></link>
<id>urn:uuid:dfc1e9ba-aea4-1e43-2c26-c78dbdd8c759</id>
<summary type="html"><![CDATA[GlobalData's clinical trial report, Critical Limb Ischemia Global Clinical Trials Review, H2, 2016" provides an overview of Critical Limb Ischemia clinical trials scenario.]]></summary>
<updated>2016-09-13T05:38:38+00:00</updated>
</entry>
<entry>
<title>Cation Channel Subfamily M Member 8  - Pipeline Review, H2 2016</title>
<link href="https://news.arcnewswire.com/@raghuraj123/cation-channel-subfamily-m-member-8-pipeline-review-h2-2016-dx8aanype8p6"></link>
<id>urn:uuid:7e86ea17-35d7-7839-af78-236297f5cc4a</id>
<summary type="html"><![CDATA[The Transient Receptor Potential Cation Channel Subfamily M Member 8 (Long Transient Receptor Potential Channel 6 or Transient Receptor Potential p8 or TRPM8) - Pipeline Review, H2 2016]]></summary>
<updated>2016-09-12T07:02:32+00:00</updated>
</entry>
<entry>
<title>Auspicious market report on Erectile Dysfunction - Pipeline Review, H2 2016</title>
<link href="https://news.arcnewswire.com/@raghuraj123/auspicious-market-report-on-erectile-dysfunction-pipeline-review-h2-2016-b68qwb65y8dj"></link>
<id>urn:uuid:a0fe275a-eb97-c7ce-7dc8-eeb03acb052a</id>
<summary type="html"><![CDATA[The Erectile Dysfunction - Pipeline Review, H2 2016 report offers a comprehensive insight on the Erectile Dysfunction pipeline landscape.]]></summary>
<updated>2016-09-07T05:20:13+00:00</updated>
</entry>
<entry>
<title>Market artifice report on Influenza B Infections - Pipeline Review, H2 2016</title>
<link href="https://news.arcnewswire.com/@raghuraj123/market-artifice-report-on-influenza-b-infections-pipeline-review-h2-2016-6a356raym8xd"></link>
<id>urn:uuid:ff0eb472-902c-0cd1-7026-b265297e50b3</id>
<summary type="html"><![CDATA[The Influenza B Infections - Pipeline Review, H2 2016 report offers a comprehensive insight on the Influenza B Infections pipeline landscape.]]></summary>
<updated>2016-09-07T05:18:45+00:00</updated>
</entry>
<entry>
<title>Apocalypse report on Myasthenia Gravis - Pipeline Review, H2 2016</title>
<link href="https://news.arcnewswire.com/@raghuraj123/apocalypse-report-on-myasthenia-gravis-pipeline-review-h2-2016-dx8aanj5m8p6"></link>
<id>urn:uuid:4f31bc68-b42f-d856-7de0-26ccca9d4b5e</id>
<summary type="html"><![CDATA[The Myasthenia Gravis - Pipeline Review, H2 2016 report offers a complete overview of the pharmaceutical research and development of the pipeline products that are developed by Myasthenia Gravis.]]></summary>
<updated>2016-09-07T05:17:16+00:00</updated>
</entry>
<entry>
<title>Global research report on Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Pipeline Review, H2 2016</title>
<link href="https://news.arcnewswire.com/@raghuraj123/global-research-report-on-integrin-alpha-v-vitronectin-receptor-subunit-alpha-or-cd51-or-itgav-pipeline-review-h2-2016-dx8aanjaa8p6"></link>
<id>urn:uuid:243cb893-88c4-2171-3550-e323bcc99679</id>
<summary type="html"><![CDATA[The Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Pipeline Review, H2 2016]]></summary>
<updated>2016-09-06T06:02:20+00:00</updated>
</entry>
<entry>
<title>Learn study on the T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Pipeline Review, H2 2016</title>
<link href="https://news.arcnewswire.com/@raghuraj123/learn-study-on-the-t-cell-surface-glycoprotein-cd4-t-cell-surface-antigen-t4-leu-3-or-cd4-pipeline-review-h2-2016-nx8xbdyep8r7"></link>
<id>urn:uuid:2b36c177-b536-50a4-094c-4f3f7b758ad3</id>
<summary type="html"><![CDATA[The T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Pipeline Review, H2 2016]]></summary>
<updated>2016-09-06T05:59:43+00:00</updated>
</entry>
<entry>
<title>Recently published market research report on Dual Specificity Mitogen Activated Protein Kinase Kinase 2  - Pipeline Review, H2 2016</title>
<link href="https://news.arcnewswire.com/@raghuraj123/recently-published-market-research-report-on-dual-specificity-mitogen-activated-protein-kinase-kinase-2-pipeline-review-h2-2016-qw8dekqw436n"></link>
<id>urn:uuid:be4e6c6c-99e3-29d3-a013-795a6eafc012</id>
<summary type="html"><![CDATA[The Dual Specificity Mitogen Activated Protein Kinase Kinase 2 (ERK Activator Kinase 2 or MAPK/ERK Kinase 2 or MAP2K2 or EC 2.7.12.2) - Pipeline Review, H2 2016]]></summary>
<updated>2016-09-06T05:56:17+00:00</updated>
</entry>
</feed>